Eslicarbazepine acetate (ESL) was labelled for add-on treatment of adults with focal epilepsies in 2009. ESL is a derivative of carbamazepine and oxcarbazepine (OXC) that promises potentially better effectiveness. It has not yet been investigated how to switch from OXC to ESL and if this switch causes any clinical changes.
Useful keywords (using NLM MeSH Indexing)
Drug Therapy, Combination
Find related publications in this database (Keywords)Oxcarbazepine